Across development platforms and enabling technologies, new investments and product roadmaps are focusing on scaling data capture, manufacturing flexibility, and agentic support for drug discovery. Wacker is launching contract research services for nucleic-acid-based therapies at its Munich center, offering R&D-grade pDNA, RNA, and LNP development support designed to connect early-stage work with GMP manufacturing transfer for clinical material. The offering is positioned as a way to reduce early development costs and to support smaller startups that need to validate constructs and lipid formulations. Oxford Nanopore also previewed new throughput and multiomics features for sequencing workflows, including multiplex direct RNA kits capable of analyzing up to 24 samples per flow cell and updates to its Q-Line GridIon portfolio and PromethIon flow cell options to boost data output per run. The roadmap signals continuing competitive pressure on sequencing capacity, accuracy, and operational efficiency for biopharma and clinical customers. Qiagen announced plans to integrate Nvidia computing and the BioNeMo platform into its digital insights knowledgebases, using graph-based AI and accelerated computing to support target and biomarker discovery through evidence-linked reasoning. Together, the developments point to enabling layers—CDx and sequencing pipelines, and compute and manufacturing services—becoming core infrastructure for biotech timelines rather than back-office utilities.